CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients

In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Chavaz, Lara, Royston, Léna, Masouridi-Levrat, Stavroula, Mamez, Anne-Claire, Giannotti, Federica, Morin, Sarah, Van Delden, Christian, Chalandon, Yves, Neofytos, Dionysios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147386/
https://www.ncbi.nlm.nih.gov/pubmed/37125233
http://dx.doi.org/10.1093/ofid/ofad169
_version_ 1785034789369151488
author Chavaz, Lara
Royston, Léna
Masouridi-Levrat, Stavroula
Mamez, Anne-Claire
Giannotti, Federica
Morin, Sarah
Van Delden, Christian
Chalandon, Yves
Neofytos, Dionysios
author_facet Chavaz, Lara
Royston, Léna
Masouridi-Levrat, Stavroula
Mamez, Anne-Claire
Giannotti, Federica
Morin, Sarah
Van Delden, Christian
Chalandon, Yves
Neofytos, Dionysios
author_sort Chavaz, Lara
collection PubMed
description In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir.
format Online
Article
Text
id pubmed-10147386
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-101473862023-04-29 CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients Chavaz, Lara Royston, Léna Masouridi-Levrat, Stavroula Mamez, Anne-Claire Giannotti, Federica Morin, Sarah Van Delden, Christian Chalandon, Yves Neofytos, Dionysios Open Forum Infect Dis Brief Report In this single-center study of 61 allogeneic hematopoietic cell transplant (HCT) recipients receiving letermovir primary cytomegalovirus (CMV) prophylaxis for the first 100 days, we report 23% incidence of clinically significant CMV infection during the first 100 days after letermovir discontinuation, predominately in haploidentical HCT recipients, without any associations with CMV-DNAemia under letermovir. Oxford University Press 2023-03-27 /pmc/articles/PMC10147386/ /pubmed/37125233 http://dx.doi.org/10.1093/ofid/ofad169 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Chavaz, Lara
Royston, Léna
Masouridi-Levrat, Stavroula
Mamez, Anne-Claire
Giannotti, Federica
Morin, Sarah
Van Delden, Christian
Chalandon, Yves
Neofytos, Dionysios
CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
title CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
title_full CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
title_fullStr CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
title_full_unstemmed CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
title_short CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
title_sort cmv infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147386/
https://www.ncbi.nlm.nih.gov/pubmed/37125233
http://dx.doi.org/10.1093/ofid/ofad169
work_keys_str_mv AT chavazlara cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT roystonlena cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT masouridilevratstavroula cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT mamezanneclaire cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT giannottifederica cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT morinsarah cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT vandeldenchristian cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT chalandonyves cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients
AT neofytosdionysios cmvinfectionafterletermovirprimaryprophylaxisdiscontinuationinallogeneichematopoieticcelltransplantrecipients

Ejemplares similares